Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
New Ovarian Cancer Drug Extends Survival in Resistant Disease "Practice changing" findings for tough-to-treat patient population Jun 04, 2023
Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib Jun 03, 2023
Many With Cancer Predisposition Diseases Unaware of Genetic Status Moreover, a significant proportion do not qualify for genetic screening under current guidelines Apr 19, 2023
Risks Outweigh Benefits for BSO at Benign Hysterectomy in Younger Women It's less clear-cut for postmenopausal women, study authors say Apr 18, 2023
VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy Prospective study in heavily treated population is warranted, researcher says Mar 30, 2023
Novel Strategies Show Winning Potential in Ovarian Cancer High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib Mar 28, 2023
CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer Responses in a fourth of patients, clinical benefit in up to 90% Mar 26, 2023
OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancer Significant PFS results demonstrated in NORA trial don't extend to overall survival Dec 17, 2022
FDA OKs First Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancer Mirvetuximab soravtansine produced responses in almost a third of patients in pivotal trial Nov 15, 2022
Pandemic Led to Surgical Delays in Gynecologic Cancers, and Worse Outcomes One in five patients experienced changes in their care plan Oct 04, 2022
Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says Oct 01, 2022
'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancer Post-hoc data from SOLO3 show diverging results based on prior lines of therapy Sep 30, 2022
Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancer A closer look at why PARP inhibitor's third-line indication was withdrawn Sep 09, 2022
Does PARP Inhibitor Maintenance Induce Platinum Resistance in Ovarian Cancer? Shorter progression-free interval with platinum chemotherapy after olaparib maintenance Sep 01, 2022
Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer Lower all-cause, cancer-specific mortality in women who received the drugs around time of surgery Aug 29, 2022
Two Sides of Endosalpingiosis: Benign Growth or Harbinger of Cancer? Concurrent malignancy more than twice as common as compared with endometriosis, study showed Aug 06, 2022
Prosthetic Mesh May Stand in the Way of Further Abdominal Operations Prior incisional hernia repair associated with complications with later abdominal surgery Aug 04, 2022
Another Possible Use for Aspirin: Reducing Ovarian Cancer Risk Potential benefit seen in women with and without established cancer risk factors Jul 27, 2022
Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancer Decision on rucaparib follows negative OS signal and "discussions" with FDA Jun 17, 2022
PARP Inhibitor Picks Up a Win in Frontline Maintenance for Ovarian Cancer Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy Jun 07, 2022
New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
Novel ADC Promising in Tough-to-Treat Ovarian Cancer Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease Mar 20, 2022
Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancer Study suggests no improvement in overall survival Mar 19, 2022
Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancer Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
A Better Option for Preserving Fertility in Gynecologic Cancer Patients? In vitro maturation can result in both embryos and oocyte vitrification, researcher says Oct 19, 2021
Christiane Amanpour's Ovarian Cancer and the Importance of Early Detection Renowned reporter calls on women to advocate for themselves Oct 11, 2021
Another Checkpoint Inhibitor Misses Mark in Ovarian Cancer No OS or PFS benefit with nivolumab versus chemotherapy for platinum-resistant disease Sep 24, 2021
Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed Sep 17, 2021
Third Dose a Charm in Israel? Door-to-Door 'Goons'; Cervids Catch COVID, Too! A daily roundup of news on COVID-19 and the rest of medicine Jul 30, 2021
COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
Ovarian Cancer Screening Trial Still Sees No Death Reduction Researchers "disappointed" by long-term results of U.K. study of 200,000 postmenopausal women May 22, 2021
Report: Worst Hospitals for Unnecessary Procedures Lown Institute says report is the first to name hospitals with high rates of overuse May 04, 2021
Triage System Gets High Marks for Ovarian Cancer Debulking Surgery Key factors predicted threefold higher risk of 90-day mortality with primary surgery Mar 26, 2021
HIPEC Combo Doubles PFS in Advanced Ovarian Cancer Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study Mar 26, 2021
Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer Ixabepilone plus bevacizumab yielded responses in a third of patients Mar 26, 2021
Androgen Receptor Inhibitor Active in Endometrial Cancer SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
